Skip Navigation

Jeffrey Rubens, M.D.

Jeffrey Rubens, M.D.

Headshot of Jeffrey Rubens
  • Assistant Professor of Oncology

Expertise

Germ Cell Tumors, Pediatric Brain Tumors

Research Interests

Epigenetics, Metabolomics, Drug Development, Pediatric Neuro-Oncology ...read more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment

Locations

The Johns Hopkins Hospital (Main Entrance)

Appointment Phone: 443-997-1508
1800 Orleans St.
Baltimore, MD 21287 map

Background

Jeffrey Rubens, M.D. is an Assistant Professor of Oncology and Pediatrics at the Johns Hopkins University School of Medicine.

Dr. Rubens received his undergraduate degree in Biology from Bowdoin College followed by a Medical Degree at Georgetown University School of Medicine. He then completed his Pediatric Residency at Northwestern University Feinberg School of Medicine and his fellowship training in Pediatric Hematology/Oncology and Neuro-Oncology at Johns Hopkins Hospital before joining the faculty at Johns Hopkins.

With a focus on Neuro-Oncology and germ cell tumors, Dr. Rubens sees patients in the Pediatric Oncology outpatient clinic at the Johns Hopkins Hospital.

Dr. Rubens' research focuses on developing new precision therapies that will rapidly translate into clinical trials aimed at reducing morbidity and improving survival in pediatric brain tumors.

...read more

Titles

  • Assistant Professor of Oncology

Departments / Divisions

Education

Degrees

  • MD; Georgetown University School of Medicine (2009)

Residencies

  • Pediatrics; McGaw Medical Center of Northwestern University (2012)

Fellowships

  • Pediatric Oncology; Johns Hopkins University School of Medicine (2017)

Board Certifications

  • American Board of Pediatrics (Pediatric Hematology-Oncology) (2017)
  • American Board of Pediatrics (Pediatrics) (2012)

Research & Publications

Research Summary

Dr. Rubens studies how unique regulatory interactions between proto-oncogenes, metabolomics, and epigenomics drive pediatric brain tumor growth and survival. He looks for vulnerabilities in these regulatory pathways that can be inhibited to selectively target aggressive pediatric brain tumors and improve survival while reducing treatment-related morbidities.

Dr. Rubens takes a “bench-to-bedside” approach aimed at rapidly translating studies into new clinical trials to improve therapies for children suffering from aggressive brain tumors.

Is this you? Edit Profile
back to top button